The expanding role of pertuzumab in the treatment of HER2-positive breast cancer.

Breast Cancer (Dove Med Press) · 2015 · PMC4445592 · PMID 26056489

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

20 At the time of the independent assessment of PFS, the interim analysis of OS showed a trend in favor of the pertuzumab group, but this was not significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.